Yuhan Corp’s new anticancer drug, ‘Leclaza’ is gradually expanding its influence in the domestic market. The drug exceeded KRW 30 billion in cumulative sales in only 2 years since its domestic release. Prescriptions are also expected to increase further if the company receives reimbursement for its newly added indication as a first-line treatment.

According to the market research institution IQVIA on the 25th, Leclaza posted sales of KRW 10.3 billion in 1H, up 49.5% YoY. In Q1, sales increased by 57.4% YoY to KRW 5.1 billion and then increased by 42.5% YoY to reach KRW 5.2 billion in Q2.

Leclaza is a non-small cell lung cancer treatment that was approved as Korea’s 31st homegrown novel